To investigate the effect of intravenously administered (IV) Golimumab (2 mg/kg), an anti-TNFα monoclonal antibody, on sleep problems, total back pain, and night back pain in adult patients (pts) with active Ankylosing Spondylitis (AS). Methods: GO-ALIVE is a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Pts (aged ≥18 years) had a diagnosis of definite AS (per modified New York criteria) and BASDAI ≥4, total back pain visual analogue scale (VAS) ≥4, and CRP ≥0.3mg/dL. At baseline, 208 pts were randomized to IV golimumab 2mg/kg (N=105) at Wks 0, 4, and every 8 wks or placebo (N=103) at Wks 0, 4, and 12, with crossover to IV golimumab at Wk 16 and through Wk 52. Sleep problems were assessed using the Medical Outcomes Study Sleep Scale (MOS-SS, range 0-100), a generic instrument designed to assess six dimensions of sleep, including 1) Sleep disturbance, 2) Somnolence, 3) Sleep adequacy, 4) Snoring, 5) Awaken short of breath or headache, and 6) Quantity of sleep/optimal sleep during the past 4 wks. The six dimensions are also used to generate the composite Sleep Problems Index. An increase in score from baseline represents improvement. Total back pain and night back pain over the past wk were assessed using VAS (0-10 cm; 0=no pain, 10=most severe pain). Wk 28 results are presented here. Unadjusted p-values of least square mean differences (LSMD) between treatment groups were based on analysis of covariance (ANCOVA) controlling for prior anti-TNF therapy. Results: Mean changes in MOS-SS Sleep Index and 6 subscales are presented in Table 1 . Improvement (p<0.05) in the MOS-SS sleep index and 4 subscales at Wk 8 was observed in golimumab compared to placebo, and in the sleep index and 4 subscales at Wk 16. Improvements from baseline to Wks 8 and 16 in pts' assessment of total back pain (cm) were greater (p<0.001) in golimumab than placebo (-2.70 vs -0.86 and -3.15 vs -1.15, respectively), and after placebo crossed over to golimumab, the differences diminished at Wk 28 (-3.14 vs -3.34, respectively). Improvements at Wks 8 and 16 from baseline in pts' assessment of night back pain (cm) were also greater (p<0.001) in golimumab than placebo (-3.03 vs -0.87 and -3.44 vs -0.85, respectively), and differences diminished at Wk 28 (-3.47 vs -3.42, respectively). Changes from baseline in all subscales of MOS-SS were correlated (Spearman correlations ranging between -0.10 and -0.45) with total back pain (TBP) and night back pain (NBP) at Wks 8, 16, and 28 (p values <0.05), with the exception of Snoring and both TBP and NBP at Wk 16. Change in NBP was associated with change in Sleep Problem Index at all 3 time points (p=0.002, p=0.001, and p=0.031, respectively). In the general linear model, most of the association between change in TBP and change in Sleep Problem Index was explained by the association between change in NBP and change in Sleep Problem Index.
Objectives:
To investigate the effect of intravenously administered (IV) Golimumab (2 mg/kg), an anti-TNFα monoclonal antibody, on sleep problems, total back pain, and night back pain in adult patients (pts) with active Ankylosing Spondylitis (AS). Methods: GO-ALIVE is a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Pts (aged ≥18 years) had a diagnosis of definite AS (per modified New York criteria) and BASDAI ≥4, total back pain visual analogue scale (VAS) ≥4, and CRP ≥0.3mg/dL. At baseline, 208 pts were randomized to IV golimumab 2mg/kg (N=105) at Wks 0, 4, and every 8 wks or placebo (N=103) at Wks 0, 4, and 12, with crossover to IV golimumab at Wk 16 and through Wk 52. Sleep problems were assessed using the Medical Outcomes Study Sleep Scale (MOS-SS, range 0-100), a generic instrument designed to assess six dimensions of sleep, including 1) Sleep disturbance, 2) Somnolence, 3) Sleep adequacy, 4) Snoring, 5) Awaken short of breath or headache, and 6) Quantity of sleep/optimal sleep during the past 4 wks. The six dimensions are also used to generate the composite Sleep Problems Index. An increase in score from baseline represents improvement. Total back pain and night back pain over the past wk were assessed using VAS (0-10 cm; 0=no pain, 10=most severe pain). Wk 28 results are presented here. Unadjusted p-values of least square mean differences (LSMD) between treatment groups were based on analysis of covariance (ANCOVA) controlling for prior anti-TNF therapy. Results: Mean changes in MOS-SS Sleep Index and 6 subscales are presented in Table 1 . Improvement (p<0.05) in the MOS-SS sleep index and 4 subscales at Wk 8 was observed in golimumab compared to placebo, and in the sleep index and 4 subscales at Wk 16. Improvements from baseline to Wks 8 and 16 in pts' assessment of total back pain (cm) were greater (p<0.001) in golimumab than placebo (-2.70 vs -0.86 and -3.15 vs -1.15, respectively) , and after placebo crossed over to golimumab, the differences diminished at Wk 28 (-3.14 vs -3.34, respectively) . Improvements at Wks 8 and 16 from baseline in pts' assessment of night back pain (cm) were also greater (p<0.001) in golimumab than placebo (-3.03 vs -0.87 and -3.44 vs -0.85, respectively) , and differences diminished at Wk 28 (-3.47 vs -3.42, respectively) . Changes from baseline in all subscales of MOS-SS were correlated (Spearman correlations ranging between -0.10 and -0.45) with total back pain (TBP) and night back pain (NBP) at Wks 8, 16, and 28 (p values <0.05) , with the exception of Snoring and both TBP and NBP at Wk 16. Change in NBP was associated with change in Sleep Problem Index at all 3 time points (p=0.002, p=0.001, and p=0.031, respectively). In the general linear model, most of the association between change in TBP and change in Sleep Problem Index was explained by the association between change in NBP and change in Sleep Problem Index.
Conclusions: Adult pts with active AS treated with IV golimumab showed improvements in sleep problems, total back pain, and night back pain. Night back pain improvement was associated with improvement in sleep problems. Disclosure of Interest: A. Deodhar Grant/research support from: Janssen, Amgen, Abbvie, GSK, Eli Lilly, Novartis, Pfizer, UCB, Consultant for: Janssen, Eli Lilly, Novartis, Pfizer, UCB, J. Reveille Grant/research support from: Janssen Scientific Affairs, LLC., E. Chan Employee of: Janssen Global Services, LLC, S. Background: Large-scale real life observational cohorts are needed to study effectiveness and early signals of rare safety issues of new biological disease modifying drugs (bDMARDs) and biosimilars (bsDMARDs) in ankylosing spondylitis (AS). Combining data from biological registries would facilitate this. The Nordic countries have several similarities that would justify such aggregated analyses including similar health care systems with universal access to population based health care, availability of b/bsDMARDs through a tax-paid system and the registration of use and effectiveness of bDMARDs in inflammatory diseases in a prospective manner in drug registries. Objectives: To explore the prescription patterns of old (TNF-inhibitors) and newer bDMARDs (secukinumab, ustekinumab) including bsDMARDs (SB4, CT-P13) over time in AS in the Nordic countries in order to illustrate the potential of a common Nordic collaboration. Methods: Data regarding the numbers of AS patients (pts) (ICD10 code M45) who initiated bDMARD treatment (irrespective of treatment course number) during the period 2011-2016 were collected from the Nordic rheumatologic biological registries SRQ (Sweden), NOR-DMARD (6 Norwegian treatment centres), DANBIO (Denmark), ROB-FIN (Finland, 2011 -2015 and ICEBIO (Iceland) . Results: In total, 6,610 bDMARD treatment initiations were identified (Sweden 3654, Norway 1078, Denmark 782, Finland 789, Iceland 307). The prescription patterns of bDMARDs changed substantially over time. In 2016, the number of pts initiating a bsDMARDs exceeded those starting an originator bDMARD (figure). Few patients were treated with ustekinumab (Denmark <10 pts, Finland <10, Sweden 26) and secukinumab (Denmark <10 pts, Sweden 57).
Conclusions:
The use of bsDMARDs in AS is rapidly increasing. The use of drugs with new modes of action is still low, which illustrates the need for collaboration across countries to provide real life data with sufficient power for new innovative therapies in the future. The Nordic rheumatologic registries represent a unique opportunity to study effectiveness and safety of bDMARDs, including bsDMARDs in AS. (infliximab, etanercept, adalimumab, golimumab and certolizumab pegol) in ankylosing spondylitis (AS) is effective. However, evidence regarding the potential efficacy of these anti-TNF drugs in the extra-articular manifestations of ankylosing spondylitis, namely in uveitis (UV), inflammatory bowel disease (IBD) and dactylitis is scarce. Objectives: To analyze evidence on efficacy of anti-TNF drugs approved for AS treatment in UV, IBD and dactylitis associated with AS. Methods: A systematic literature review was performed using the PubMed and Cochrane Library databases. Randomized controlled trials (RCT), metaanalyzes and observational studies (OS) reporting efficacy of anti-TNF agents in extra-articular manifestations of AS were included. Results: Fifty studies were included (seventeen RCTs, six meta-analyses and twenty seven observational studies). From the RCT we extracted the results presented in Table 1 for uveitis and in Table 2 for IBD. None reported results for dactylitis. Of the meta-analyzes included, only one presents results. These one shows that the incidence of uveitis is lower in patients taking etanercept than placebo (incidence of 8.6 and 19.3 per 100 patients per year, respectively; p value =0.03). In OS comparing different drugs, in one the risk of developing uveitis was 1.9 times higher in patients under etanercept compared to those under adalimumab (p value =0.0223) and a risk similar to those under infliximab and those under adalimumab. In another we have a percentage of patients with uveitis, during the course of the study, under etanercept of 8.0% and under infliximab of 4.0%. In the OS, the percentage of patients with UV events with infliximab was in a range of 0.0%>3.1% with a follow-up interval between 2 years and 5 years; with etanercept was 0.9%>29.6% and a follow-up time interval between 12 weeks to 7 years; with adalimumab there is only one study with duration of 2 years reporting 3.9% UV events. Regarding IBD reported in OS, there was 3.7%>7.7% patients with events under treatment with etanercept over a follow-up time of 3.2-7 years; with adalimumab only a 2-year study reported IBD in 0.6% of cases. We did not find results regarding for other extra-articular manifestations or anti-TNF drugs.
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